The large global burden of respiratory syncytial virus (RSV) respiratory tract infections in
young children and older adults has gained increased recognition in recent years. Recent …

After decades of work, several interventions to prevent severe respiratory syncytial virus
(RSV) disease in high-risk infant and older adult populations have finally been approved …

Nirsevimab is a monoclonal antibody that binds to the respiratory syncytial virus (RSV)
fusion protein. During the Phase 2b (NCT02878330) and MELODY (NCT03979313) clinical …

OBJECTIVES The 2022 seasonal respiratory syncytial virus (RSV) epidemic in Sydney,
Australia saw an unprecedented number of RSV detections. We aimed to characterize …

Introduction Nirsevimab, a monoclonal antibody for the prevention of disease caused by
respiratory syncytial virus (RSV), has recently been approved for use in Europe and Spain …

Respiratory syncytial virus (RSV) is the second most common pathogen causing infant
mortality. Additionally, RSV is a major cause of morbidity and mortality in older adults (age≥ …

The respiratory syncytial virus (RSV) causes a substantial burden worldwide. After over six
decades of research, there is finally a licensed immunization option that can protect the …

Human respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract
infections (LRTI) in young children and elderly people worldwide. Recent significant …

Respiratory syncytial virus (RSV) is a leading cause of acute respiratory infection amongst
all ages, causing a significant global health burden. Preventative and therapeutic options for …

Since the initial isolation in 1956 of what is now identified as respiratory syncytial virus
(RSV), seasonal outbreaks of illness attributable to this enigmatic respiratory virus have …